Table 1 Baseline characteristics of the overall and model population
| Â | Overall population | Known | Model population | Known |
|---|---|---|---|---|
General characteristics | N (%)/Mean (±SD) | N (%) | N (%)/Mean (±SD) | N (%) |
N total | 1247 | Â | 748 | Â |
Age (years) | 66.4 (±11.8) | 1243 (99.7%) | 67.3 (±11.6), | 748 (100%) |
Sex, males | 752 (60.4%) | 1245 (99.8%) | 471 (63.0%) | 748 (100%) |
BMI (kg/m2) | 26.5 (±5.5) | 1129 (90.5%) | 26.2 (±5.29) | 696 (93.0%) |
Current smokers | 577 (46.6%) | 1239 (99.4%) | 328 (44.1%) | 744 (99.5%) |
Ex-smokers | 662 (53.4%) | 1239 (99.4%) | 416 (55.9%) | 744 (99.5%) |
Lung function | ||||
 FEV1/FVC | 59.0% (±15.6) | 1149 (92.1%) | 53.1% (±11.5) | 748 (100%) |
 FEV1 %Ref | 54.9% (±20.8) | 1088 (87.2%) | 49.5% (±17.4) | 718 (96.0%) |
 FVC %Ref | 69.6% (±19.3) | 1099 (88.1%) | 69.5% (±18.9) | 718 (96.0%) |
 No COPD | 268 (24.3%) | 1101 (88.3%) | 0 (0%) | 718 (96.0%) |
 GOLD 1 | 40 (3.63%) | 1101 (88.3%) | 32 (4.46%) | 718 (96.0%) |
 GOLD 2 | 351 (31.9%) | 1101 (88.3%) | 303 (42.2%) | 718 (96.0%) |
 GOLD 3 | 323 (29.3%) | 1101 (88.3%) | 287 (40.0%) | 718 (96.0%) |
 GOLD 4 | 119 (10.8%) | 1101 (88.3%) | 96 (13.4%) | 718 (96.0%) |
Symptoms | ||||
 mMRC dyspnea scale 0–1 | 610 (50.8%) | 1201 (96.3%) | 355 (49.0%) | 725 (96.9%) |
 mMRC dyspnea scale 2 | 350 (29.1%) | 1201 (96.3%) | 219 (30.2%) | 725 (96.9%) |
 mMRC dyspnea scale 3 | 199 (16.6%) | 1201 (96.3%) | 129 (17.8%) | 725 (96.9%) |
 mMRC dyspnea scale 4 | 42 (3.50%) | 1201 (96.3%) | 22 (3.03%) | 725 (96.9%) |
 Cough | 864 (69.4%) | 1245 (99.8%) | 515 (68.9%) | 747 (99.9%) |
 Sputum | 731 (58.8%) | 1243 (99.7%) | 446 (59.7%) | 747 (99.9%) |
Pharmacological COPD treatment | ||||
 Short-acting bronchodilators | 466 (37.5%) | 1242 (99.6%) | 294 (39.4%) | 747 (99.9%) |
 Long-acting ß2-agonists (LABA) | 355 (28.7%) | 1237 (99.2%) | 235 (31.5%) | 745 (99.6%) |
 Long-acting muscarinic antagonists (LAMA) | 509 (41.1%) | 1238 (99.3%) | 345 (46.2%) | 746 (99.7%) |
 Inhaled corticosteroids (ICS) | 270 (21.8%) | 1237 (99.2%) | 178 (23.8%) | 747 (99.9%) |
 Inhaled combination therapy (LABA+ICS) | 632 (50.9%) | 1242 (99.6%) | 390 (52.1%) | 748 (100%) |
 Systemic corticosteroids | 73 (5.89%) | 1240 (99.4%) | 42 (5.61%) | 748 (100%) |
Comorbidities | ||||
 Asthma | 221 (20.6%) | 1073 (86.0%) | 130 (19.9%) | 654 (87.4%) |
 Diabetes mellitus | 141 (13.1%) | 1074 (86.1%) | 86 (13.1%) | 655 (87.6%) |
 Hypertension | 601 (55.8%) | 1078 (86.4%) | 366 (55.9%) | 655 (87.6%) |
 Coronary heart disease | 228 (21.2%) | 1075 (86.2%) | 148 (22.6%) | 655 (87.6%) |
 Heart failure | 159 (14.8%) | 1073 (86.0%) | 96 (14.7%) | 654 (87.4%) |
 Cancer (other than lung cancer) | 52 (4.85%) | 1072 (86.0%) | 36 (5.51%) | 653 (87.3%) |
 Lung cancer | 29 (2.70%) | 1073 (86.0%) | 16 (2.45%) | 654 (87.4%) |
 Cerebrovascular Insult (CVI) | 36 (3.36%) | 1073 (86.0%) | 24 (3.67%) | 654 (87.4%) |
Physical activity | ||||
 Sports (at least twice a week) | 334 (28.2%) | 1183 (94.9%) | 200 (27.6%) | 724 (96.8%) |
 Pulmonary rehabilitation | 86 (7.01%) | 1226 (98.3%) | 55 (7.40%) | 743 (99.3%) |